tiprankstipranks
Tryptamine Therapeutics Limited (AU:TYP)
:TYP
Australian Market

Tryptamine Therapeutics (TYP) Financial Statements

Compare
11 Followers

Tryptamine Therapeutics Financial Overview

Tryptamine Therapeutics's market cap is currently AU$48.50M. The company's EPS TTM is AU$-0.013; its P/E ratio is ―; Tryptamine Therapeutics is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is AU$―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Jun 21Jun 20Jun 19
Income Statement
Total Revenue
Gross Profit$ 99.73K-$ 2.62M-
Operating Income$ -14.11M$ -12.67M$ -8.00M$ -2.31M
EBITDA$ -8.27M$ -11.66M$ -7.62M$ -2.31M
Net Income$ -10.08M$ -8.47M$ -5.28M$ -2.28M
Balance Sheet
Cash & Short-Term Investments$ ―$ ―$ ―$ ―
Total Assets$ 13.61M$ 21.46M$ 6.54M$ 5.40M
Total Debt$ 3.74M$ 1.36M$ 912.87K$ 0.00
Net Debt$ -1.10M$ -11.37M$ -830.05K$ -4.42M
Total Liabilities$ 4.81M$ 2.59M$ 1.53M$ 281.00K
Stockholders' Equity$ ―$ ―$ ―$ ―
Cash Flow
Free Cash Flow$ -9.65M$ -9.45M$ -7.33M$ -3.04M
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Currency in USD

Tryptamine Therapeutics Earnings and Revenue History

Tryptamine Therapeutics Debt to Assets

Tryptamine Therapeutics Cash Flow

Tryptamine Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis